Scarica l'app Stockscreener
12.96
1.82%
-0.24
Amneal Pharmaceuticals Inc Borsa (AMRX) Ultime notizie
Is Amneal Pharmaceuticals Inc. stock overvalued by current metricsJuly 2025 Volume & Long Hold Capital Preservation Tips - ulpravda.ru
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance - PharmiWeb.com
A Look At Amneal Pharmaceuticals (AMRX) Valuation As Analyst Optimism And Revenue Outlook Support Recent Momentum - Sahm
KeifeRx and Amneal partner on Parkinson’s disease drug development By Investing.com - Investing.com Canada
KeifeRX announces research collaboration & option agreement with Amneal Pharmaceuticals - MarketScreener
KeifeRx Announces Research Collaboration and Option Agreement with Amneal Pharmaceuticals to Advance KFRX06, a Brain-Penetrant LRRK2 Program for Parkinson’s Disease - Business Wire
Will Amneal Pharmaceuticals Inc. stock recover faster than peersRecovery Day Options & how to pick the right width - ulpravda.ru
Can Amneal Pharmaceuticals Inc. stock continue upward trendJuly 2025 Closing Moves & Breakout Confirmation Trade Signals - ulpravda.ru
Why Amneal Pharmaceuticals Inc. stock remains a top recommendationMarket Risk Summary & Breakout Confirmation Trade Signals - ulpravda.ru
Smart Money: Will Amneal Pharmaceuticals Inc. stock benefit from upcoming earnings reportsEarnings Miss & AI Enhanced Market Trend Forecasts - ulpravda.ru
Will Amneal Pharmaceuticals Inc. stock benefit from upcoming earnings reports2025 Price Momentum & Growth Oriented Trading Recommendations - ulpravda.ru
Is Amneal Pharmaceuticals Inc. stock vulnerable to regulatory risksTrade Risk Summary & Weekly Market Pulse Alerts - ulpravda.ru
What is the fair value of Amneal Pharmaceuticals Inc. stock nowFinancial Sector Performance & Superior Trading Portfolio - ulpravda.ru
Can This Healthcare Stock Keep Going After a Nearly 70% Surge? - Barchart.com
Amneal Pharmaceuticals, Inc. (AMRX) Stock Analysis: Unveiling a 10% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Amneal Pharmaceuticals (NASDAQ:AMRX) Reaches New 12-Month HighShould You Buy? - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $13.04 By Investing.com - Investing.com Canada
Assessing Amneal Pharmaceuticals (AMRX) Valuation After Strong Multi Year Shareholder Returns - Yahoo Finance
Allspring Global Investments Holdings LLC Boosts Stock Position in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
How Recent Q3 Beats And FDA Wins Are Shaping The Amneal Pharmaceuticals (AMRX) Story - Yahoo Finance
Latest FDA Denosumab Decisions Offer Mixed Verdicts - Citeline News & Insights
Suboxone Market is Going to Booming Growth 2025 With Top Key - openPR.com
Amneal Launches Complex Generic Fluorometho-lone Ophthalmic Suspension - Specialty Pharmacy Continuum
Amneal Pharma-mAbxience gets USFDA approval for Boncresa, Oziltus - Medical Dialogues
Amneal Pharmaceuticals stock hits 52-week high at $12.99 By Investing.com - Investing.com Nigeria
Amneal Pharmaceuticals stock hits 52-week high at $12.99 - Investing.com
How Amneal Pharmaceuticals Inc. stock trades during market volatilityDividend Yield Trends & Join a Community of Smart Investors - Bollywood Helpline
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Short Squeeze: Why Amneal Pharmaceuticals Inc stock remains a top recommendation2025 Key Highlights & Community Verified Watchlist Alerts - moha.gov.vn
FDA approves Amneal’s two denosumab biosimilars for US market By Investing.com - Investing.com Nigeria
Amneal stock rises after FDA approves two denosumab biosimilars By Investing.com - Investing.com Australia
Amneal Reports FDA Approval of Denosumab Biosimilars - marketscreener.com
Amneal stock rises after FDA approves two denosumab biosimilars - Investing.com
FDA approves Amneal’s two denosumab biosimilars for US market - Investing.com
Amneal Announces FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA® - The Manila Times
Amneal Pharmaceuticals (AMRX): Valuation Check After FDA Approval for New Epinephrine Injection - Sahm
Assenagon Asset Management S.A. Raises Holdings in Amneal Pharmaceuticals, Inc. $AMRX - MarketBeat
Market Leaders: What insider trading reveals about Amneal Pharmaceuticals Inc. stockJuly 2025 Momentum & High Return Stock Watch Alerts - Улправда
What insider trading reveals about Amneal Pharmaceuticals Inc. stockJuly 2025 Setups & Free Low Drawdown Momentum Trade Ideas - Улправда
Operating cash flow per share of Amneal Pharmaceuticals, Inc. Class A – DUS:2DT - TradingView — Track All Markets
Amneal Pharmaceuticals stock hits 52-week high at $12.69 By Investing.com - Investing.com Australia
Aug Patterns: Why Amneal Pharmaceuticals Inc. stock attracts global investorsJuly 2025 Volume & Long Hold Capital Preservation Tips - ulpravda.ru
Amneal Pharmaceuticals (NASDAQ:AMRX) Sets New 52-Week HighStill a Buy? - MarketBeat
Amneal Pharmaceuticals stock hits 52-week high at $12.69 - Investing.com
0.37%
1.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):